Literature DB >> 10844415

Medium-term cardiovascular effects of high-dose growth hormone treatment in growth hormone-deficient children.

G Radetti1, R Crepaz, C Paganini, L Gentili, W Pitscheider.   

Abstract

AIM: To investigate the possible cardiac morphofunctional alterations inducd by prolonged and high-dose GH therapy in a group of 14 children with isolated GH deficiency. PATIENTS AND METHODS: Patients were evaluated at phase 1, after 1.1 +/- 0.6 years of treatment with GH 0.93 +/- 0.13 U/kg/week, and at phase 2, after 5.5 +/- 2.1 years of therapy 0.89 +/- 0.11 U/kg/week. At each phase left ventricular volume, mass and systolic function were evaluated by two-dimensional guided M-mode echocardiography; left ventricular diastolic function was assessed by PW-Doppler sampling of transmitral flow.
RESULTS: Phase 1: diastolic blood pressure was lower (p < 0.05) and fractional shortening was not adequate for the level of afterload (stress shortening index p < 0.05) in patients compared to controls. Phase 2: diastolic blood pressure was lower (p < 0.01) and mass and mass/volume ratio were increased (mass index p < 0.05, mass/ volume ratio p < 0.05) in patients compared to controls. The increased mass/volume ratio, together with the normal systolic blood pressure, explains the reduction in peak systolic stress (p < 0.005). Among the parameters of left ventricular diastolic function, the peak E velocity/total area under mitral valve tracing and the area under E velocity/total area under mitral value tracing ratios were significantly decreased (p < 0.05).
CONCLUSION: After a mean period of 5 years on high-dose GH treatment in GH-deficient children, subclinical morphofunctional alterations in the left ventricle were found. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10844415     DOI: 10.1159/000023469

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  5 in total

1.  Cardiac functions in children with growth hormone deficiency before and during growth hormone-replacement therapy.

Authors:  Osman Ozdemir; Ayhan Abaci; Samil Hizli; Cem Hasan Razi; Ahmet Zulfikar Akelma; Mesut Kocak; Fatih Mehmet Kislal
Journal:  Pediatr Cardiol       Date:  2011-04-07       Impact factor: 1.655

2.  The effect of recombinant human growth hormone therapy on left-ventricular chamber size and function in children with growth hormone deficiency.

Authors:  Ihsan Esen; Ilker Cetin; Fatma Demirel; Filiz Ekici
Journal:  Pediatr Cardiol       Date:  2013-06-13       Impact factor: 1.655

3.  Growth hormone treatment and left ventricular dimensions in Turner syndrome.

Authors:  Lea Ann Matura; Vandana Sachdev; Vladimir K Bakalov; Douglas R Rosing; Carolyn A Bondy
Journal:  J Pediatr       Date:  2007-06       Impact factor: 4.406

Review 4.  Etiology and treatment of growth retardation in children with chronic kidney disease and end-stage renal disease: a historical perspective.

Authors:  Richard N Fine
Journal:  Pediatr Nephrol       Date:  2009-12-24       Impact factor: 3.714

5.  Evaluation of left ventricular mass and function, lipid profile, and insulin resistance in Egyptian children with growth hormone deficiency: A single-center prospective case-control study.

Authors:  Kotb Abbass Metwalley; Hekma Saad Farghaly; Heba Ahmed Abd El-Hafeez
Journal:  Indian J Endocrinol Metab       Date:  2013-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.